8-KOther Events

BIOGEN INC. 8-K Report, Corporate Update (Jan 9, 2009)

Filed January 9, 2009For Securities:BIIB

Summary

Biogen Idec Inc. (BIIB) has announced a new initiative to provide ongoing transparency regarding TYSABRI-treated patients and confirmed cases of progressive multifocal leukoencephalopathy (PML). Starting January 9, 2009, and continuing weekly through July 24, 2009, the company will post information on confirmed PML cases that have occurred in TYSABRI-treated patients since July 2006 on its corporate website. The initial posting will include only previously disclosed cases, establishing a baseline for future updates. This move demonstrates Biogen Idec's commitment to investor and public safety by providing direct access to critical safety data related to TYSABRI. Investors should monitor these website updates closely, as the frequency and nature of reported PML cases could significantly impact market perception and the company's valuation. The company's intention to maintain this disclosure for a defined period suggests a proactive approach to managing the known risks associated with TYSABRI.

Key Highlights

  • 1Biogen Idec will post weekly information on confirmed PML cases in TYSABRI-treated patients on its website.
  • 2The disclosure period will run from January 9, 2009, through July 24, 2009.
  • 3The company will provide data on PML cases occurring since July 2006.
  • 4The initial website posting will consist of previously disclosed PML cases.
  • 5This initiative aims to increase transparency regarding TYSABRI safety.
  • 6Investors can access this information at www.biogenidec.com/tpme.

Frequently Asked Questions

The main purpose of this filing is to inform investors that Biogen Idec will begin posting weekly updates on its website regarding confirmed cases of progressive multifocal leukoencephalopathy (PML) in patients treated with TYSABRI.

Biogen Idec will update the PML information weekly, starting on January 9, 2009, and continuing through July 24, 2009.

The website will contain information on confirmed cases of progressive multifocal leukoencephalopathy (PML) that have occurred in TYSABRI-treated patients since July 2006. The first posting will include only previously disclosed cases.

This information is crucial for investors as PML is a serious and potentially fatal opportunistic infection associated with TYSABRI. Regular updates on confirmed cases provide insight into the ongoing risk profile of the drug and could impact the company's stock performance and investor sentiment.